- Trials with a EudraCT protocol (117)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
117 result(s) found for: Heart rate monitor.
Displaying page 1 of 6.
EudraCT Number: 2012-001700-37 | Sponsor Protocol Number: CELL-004 | Start Date*: 2012-10-03 | |||||||||||
Sponsor Name:Celladon Corporation | |||||||||||||
Full Title: A Phase 2b, Double-Blind, Placebo-Controlled, Multinational, Multicenter, Randomized Study Evaluating the Safety and Efficacy of Intracoronary Administration of MYDICAR® (AAV1/SERCA2a) in Subjects ... | |||||||||||||
Medical condition: Moderate to advanced heart failure (NYHA class II, III or IV) due to systolic dysfunction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DE (Completed) GB (Completed) BE (Completed) PL (Completed) NL (Completed) DK (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-002960-27 | Sponsor Protocol Number: P-6708H | Start Date*: 2007-07-23 |
Sponsor Name:Pharma Nord ApS | ||
Full Title: Coenzyme Q10 as adjunctive treatment of chronic heart failure. A randomised double-blind multicenter trial with focus on Symptoms, Biomarker status (BNP) and long-term Outcome (hospitalisation/mort... | ||
Medical condition: Chronic heart failure for more than 6 weeks, in NYHA class III or IV. Age>18 years; males and females. Optimal medical treatment of heart failure according to the investigators opinion. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-013293-41 | Sponsor Protocol Number: 08/0182 | Start Date*: 2011-03-21 |
Sponsor Name:Joint UCLH/UCH Biomedical Research Unit | ||
Full Title: Randomised, double blind, phase IV study to compare the incidence of ECG changes during elective caesarean section under spinal anaesthesia when using phenylephrine or ephedrine infusion to maintai... | ||
Medical condition: uncomplicated term pregnancy. Patient undergoing elective cesarean delivery. Ephedrine and phenylephrine are vasopressors used to maintain maternal blood pressure close to normal values during spin... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2014-000771-24 | Sponsor Protocol Number: CXL-1427-02 | Start Date*: 2014-12-22 | |||||||||||
Sponsor Name:Cardioxyl Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6-Hour Intravenous Infusion of CXL-1427 in Hospitalized Patients with Systolic Heart Failure | |||||||||||||
Medical condition: Heart failure with reduced ejection fraction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001014-15 | Sponsor Protocol Number: S61372 | Start Date*: 2018-06-26 |
Sponsor Name:university hospital leuven | ||
Full Title: Frozen-thawed embryo transfer in a natural versus artificial cycle: a randomized clinical trial | ||
Medical condition: Patients with subfertility having frozen embryos after in vitro fertilization (IVF) or intracytoplasmatic sperm injection (ICSI) | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: BE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2016-002015-17 | Sponsor Protocol Number: 2016-002015-17 | Start Date*: 2017-03-10 | |||||||||||
Sponsor Name:Odense University Hospital | |||||||||||||
Full Title: Low-flow Low-gradient Aortic Stenosis – Diagnostic Usefullness of Ivabradine | |||||||||||||
Medical condition: Aortic valve stenosis with reduced ejection fraction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000540-14 | Sponsor Protocol Number: HIGHCARE | Start Date*: 2008-05-20 | |||||||||||
Sponsor Name:ISTITUTO AUXOLOGICO ITALIANO | |||||||||||||
Full Title: Role of the renin-angiotensin system in the cardiovascular, metabolic, neurologic and respiratory response to hypobaric hypoxia during sustained exposure to high altitude. | |||||||||||||
Medical condition: This study is aimed at the investigation of adaptative physiological mechanisms at high altitude and not at the development of new therapeutic indications. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-005043-86 | Sponsor Protocol Number: 1308143 | Start Date*: 2014-03-21 | |||||||||||
Sponsor Name:CHU de Saint-Etienne | |||||||||||||
Full Title: Reactivity of the autonomic nervous system after a nociceptive stress in the newborn: Interest of sucrose and non-nutritive sucking. | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001547-12 | Sponsor Protocol Number: DC2017RACELINES01 | Start Date*: 2017-12-21 |
Sponsor Name:VU University Medical Center | ||
Full Title: A phase 4, monocenter, randomized, double-blind, comparator-controlled, 3-armed parallel mechanistic intervention trial to assess the effect of 8-week empagliflozin (SGLT-2 inhibitor) monotherapy, ... | ||
Medical condition: Type 2 Diabetes Mellitus | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-000885-40 | Sponsor Protocol Number: 04-CL-1904 | Start Date*: 2020-08-27 | |||||||||||
Sponsor Name:Windtree Therapeutics, Inc. | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study on the Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock (SEISMiC) | |||||||||||||
Medical condition: Pre-Cardiogenic Shock | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) IT (Completed) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004889-10 | Sponsor Protocol Number: DapaFIT | Start Date*: 2021-04-28 |
Sponsor Name:University Hospital Tuebingen | ||
Full Title: Dapagliflozin effect on erythropoiesis and physical fitness in patients with type 2 diabetes - a randomized, partly double-blinded, controlled, three armed, parallel group, exploratory study | ||
Medical condition: Patients with T2DM and hypertension aged 40 to 70 years (including) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2015-004698-34 | Sponsor Protocol Number: ScDex_v1.0 | Start Date*: 2016-01-26 |
Sponsor Name:University Of Turku | ||
Full Title: Pharmacokinetics of subcutaneously given dexmedetomidine in healthy volunteers | ||
Medical condition: healthy volunteers are studied. | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: FI (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-012449-48 | Sponsor Protocol Number: ALS-8-09-A-101 | Start Date*: 2009-11-09 |
Sponsor Name:Air Liquide Santé International | ||
Full Title: „Sympathetic neural outflow during Xenon anesthesia in humans“ | ||
Medical condition: We would like to frame the thesis, that a general, inhalative Xenon anesthesia (1 MAC) does not effect the sympathetic outflow and the sympathetic baroreflex reagibility under spontaneous breathing... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-001818-42 | Sponsor Protocol Number: C41750/3100 | Start Date*: 2016-04-14 | |||||||||||
Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc. | |||||||||||||
Full Title: A Double-blind, Randomized, Sham–procedure–controlled, Parallel-group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (rexlemestrocel-L) in Patients with Chronic Heart Failure D... | |||||||||||||
Medical condition: Chronic Heart Failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Prematurely Ended) GB (Prematurely Ended) LT (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000896-99 | Sponsor Protocol Number: AC16148 | Start Date*: 2017-06-20 | ||||||||||||||||
Sponsor Name:University of Edinburgh [...] | ||||||||||||||||||
Full Title: A multicentre prospective randomised open-label blinded end-point controlled trial of high-sensitivity cardiac troponin I-guided combination angiotensin receptor blockade and beta blocker therapy t... | ||||||||||||||||||
Medical condition: Myocardial toxicity and the development of left ventricular systolic dysfunction | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-003462-40 | Sponsor Protocol Number: 18IC07 | Start Date*: 2020-03-30 |
Sponsor Name:Great Ormond Street Hospital for Children NHS Trust | ||
Full Title: Phase 1 , open label study of CRISPR-CAR genome edited T cells (TT52CAR19) in relapsed /refractory B Cell Acute Lymphoblastic Leukaemia | ||
Medical condition: Relapsed/ refractory B- cell acute lymphoid leukaemia | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2015-000207-13 | Sponsor Protocol Number: 2012RC22 | Start Date*: 2015-09-17 | |||||||||||
Sponsor Name:Tayside Clinical Trials Unit, University of Dundee | |||||||||||||
Full Title: Proof of concept study to assess the differential effects of chronic beta-blockade (celiprolol versus bisoprolol) on cardiopulmonary outcomes at rest and during exercise in chronic obstructive pulm... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-005097-19 | Sponsor Protocol Number: EVOLVD | Start Date*: 2019-01-23 |
Sponsor Name:Oslo University Hospital | ||
Full Title: Cholesterol lowering with EVOLocumab to prevent cardiac allograft Vasculopathy in De-novo heart transplant recipients | ||
Medical condition: Cardiac allograft vasculopathy in de-novo heart transplant recipients | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NO (Completed) DK (Completed) FI (Completed) SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-003997-33 | Sponsor Protocol Number: NOAH-AFNET6 | Start Date*: 2016-11-18 | |||||||||||
Sponsor Name:Kompetenznetz Vorhofflimmern e.V. (AFNET) [Atrial Fibrillation NETwork] | |||||||||||||
Full Title: Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes | |||||||||||||
Medical condition: Atrial fibrillation (AF) is one cause of stroke. Stroke rate is increased in patients with atrial high rate episodes (AHRE, an early stage of AF) as well, even if stroke rates are lower when compa... | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) DE (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended) BG (Completed) SE (Prematurely Ended) PL (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) PT (Prematurely Ended) GR (Completed) DK (Prematurely Ended) IT (Prematurely Ended) RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001402-20 | Sponsor Protocol Number: D910FC00001 | Start Date*: 2019-11-27 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: An Open-Label, Multi-Center, Global Study to Evaluate Long Term Safety and Efficacy in Patients Who are Receiving or Who Previously Received Durvalumab in Other Protocols (WAVE) | |||||||||||||
Medical condition: Various types of cancer ( dependent on parent study) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) FR (Completed) DE (Completed) HU (Completed) PL (Completed) ES (Ongoing) GR (Completed) BE (Completed) BG (Completed) IT (Prematurely Ended) RO (Ongoing) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
